Merislon 6 Tablet contains Betahistine dihydrochloride 6 mg as its active ingredient, a histamine analog primarily used in the management of Ménière’s disease and other vestibular disorders. Betahistine acts as a vasodilator in the inner ear, improving microcirculation and reducing endolymphatic pressure, thereby alleviating symptoms such as vertigo, tinnitus, hearing loss, and dizziness. The pharmacological action of Betahistine involves partial agonism at histamine H1 receptors and antagonism at H3 receptors, which enhances histamine release and improves vestibular compensation. Merislon 6 is indicated for patients experiencing recurrent vertigo attacks associated with vestibular dysfunction. The recommended dosage typically involves oral administration, with adjustments based on clinical response and patient tolerance. Common adverse effects are generally mild and may include gastrointestinal disturbances, headache, and allergic reactions. Caution is advised in patients with a history of peptic ulcers or asthma due to potential exacerbation. Merislon 6 should be used under medical supervision, particularly in individuals with comorbid conditions or those taking concomitant medications. Regular monitoring and adherence to prescribed dosage ensure optimal therapeutic outcomes in managing vestibular symptoms and improving patient quality of life.